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Background: The purpose of this study was to compare melancholic patients rated by the 
CORE measure of observable psychomotor disturbance with nonmelancholic and control 
subjects across a set of biomarkers.
Methods: Depressed patients were classified as melancholic or nonmelancholic by using 
the CORE measure. Both groups of patients, as well as control subjects, were compared for a 
set of clinical and laboratory measures. Serum levels of brain-derived neurotrophic factor, of 
two markers of oxidative stress (protein carbonyl content [PCC] and thiobarbituric acid reac-
tive substances [TBARS]), and of several immunity markers (interleukin [IL]-2, IL-4, IL-6, 
IL-10, IL-17, tumor necrosis factor-alpha, and interferon-gamma) were analyzed. 
Results: Thirty-three depressed patients and 54 healthy controls were studied. Depressive 
patients showed higher IL-4, IL-6, and PCC values than healthy controls. Thirteen (39%) of the 
depressed patients were assigned as melancholic by the CORE measure. They generated lower 
interferon-gamma (compared with nonmelancholic depressed patients) and TBARS (compared 
with both the nonmelancholic subset and controls) and returned higher IL-6 levels than controls. 
Both depressive groups generated higher PCC scores than controls, with no difference between 
melancholic and nonmelancholic subsets. 
Conclusion: A sign-based measure to rate melancholia was able to replicate and extend bio-
logical findings discriminating melancholic depression. Signs of psychomotor disturbance may 
be a useful diagnostic measure of melancholia. 
Keywords: melancholic depression, oxidative stress, inflammatory cytokines, brain-derived 
neurotrophic factor 
Introduction
Since the introduction of the DSM-III (Diagnostic and Statistical Manual of Mental 
Disorders, Third Edition) in the early 1980s, major depressive disorder has been 
conceptualized as a unitary entity.1,2 However, there have been a growing number of 
studies that support revising this model to position melancholia as a distinct depressive 
subtype.1,3 A number of studies have reported clinical4–8 and biological7,9–11 differences 
between patients with melancholic and nonmelancholic depression, and argued for 
differing underlying pathophysiological processes.12 However, while there is increas-
ing appreciation of melancholia as a distinct entity,13 its validity involves more precise 
clinical and biological definition. 
While the melancholic subtype (also classically known as “endogenous”, 
“autonomous”, or “type A” depression) has been historically used to name a 
clinical presentation of depression characterized by specific signs and symptoms 





(eg, nonreactivity of mood, anhedonia, and psychomotor 
disturbance), its putative pathophysiology has imputed a 
large number of potential genetic and other biological deter-
minants.14 For example, several studies have implicated an 
abnormal dexamethasone suppression test,15,16 changes in 
plasma levels of neuroactive amino acids and nitric oxide,17 
hypercortisolism,11,18 and selective responsivity to physical 
treatments, such as antidepressant drugs19 and electrocon-
vulsive therapy.20,21 However, other biological markers have 
been less studied or generated less consistent findings.
Serum brain-derived neurotrophic factor (BDNF) has 
been reported consistently as being low in depressive 
patients,22 but very few studies have compared BDNF in 
depressive subtypes. While Bus et al found no differences 
between depressive groups,23 Patas et al24 reported lower 
levels in nonmelancholic depressive patients compared with 
a control group, but no difference between melancholic 
and nonmelancholic depressive subtypes. There has also 
been a lack of studies investigating differences in oxidative 
stress markers between melancholic and nonmelancholic 
depression, although there is a growing body of evidence 
considering depression as an inflammatory disorder.25
Another growing line of research has involved inves-
tigating immune parameters across melancholic and 
nonmelancholic subtypes. However, while several studies 
have found higher proinflammatory immune activation in 
nonmelancholic depression,10,26,27 contradictory findings have 
been reported in relation to inflammatory markers. While 
interleukin (IL)-6 has been reported to be increased11,27,28 or 
normal29 in melancholic patients, other markers of T helper 
lymphocyte 1 (Th1) proinflammatory response, such as tumor 
necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), 
have been reported as increased,30 nondifferentiating,29,31,32 or 
decreased10,27 in melancholic samples. The same variability 
in findings is evident for T helper lymphocyte 2 (Th2) anti-
inflammatory markers, such as IL-10,10,31,33 as well as other 
Th1 cytokines such as IL-19,29–31,34 and IL-2.10,35 
One possible cause of the contradictory results may be 
the limited discriminatory power of the symptom-based 
DSM diagnosis of melancholia, being used in almost all 
reported studies, and which remains practically unchanged 
in DSM-5.36 In its classical definition, melancholia has as a 
“core” feature observable psychomotor disturbance (PMD, ie, 
a sign rather than a symptom).37 In several studies, Parker et al 
demonstrated a sign-based approach as being more precise in 
diagnosing melancholia than symptom-based criteria sets,38 
and suggested that the latter may confound interpretation of 
investigatory neurobiological studies.3 They developed and 
validated the CORE measure,38 now one of the most widely 
used measures of PMD in melancholia.4,5,39–41 However, 
few studies involving the CORE measure have evaluated 
biological parameters. Joyce et al reported that patients 
with CORE-defined melancholia, but not if subtyped by 
DSM-IV criteria, had greater neuroendocrine dysfunction,40 
with a blunted thyroid-stimulating hormone response after 
infusion of thyrotrophin-releasing hormone and higher 
afternoon cortisol levels. Mitchell42 reported a higher rate 
of nonsuppression on the dexamethasone suppression test in 
melancholic patients defined by the CORE measure, but not 
by DSM-III criteria. While many studies link depression with 
immune dysregulation43–45 via an imbalanced production of 
proinflammatory/anti-inflammatory cytokines, neurotrophin 
changes,46,47 and increased oxidative stress,48,49 there are no 
studies examining these biological markers in relation to the 
CORE measure. In summary, despite evidence supporting 
melancholia as a distinctive depressive subtype, neurobio-
logical differences between melancholic and nonmelancholic 
depression remain unclear.
Therefore, the aim of this study was to compare potential 
neurobiological parameters of melancholic and nonmelan-
cholic depressed patients subtyped by the CORE measure 
and also as compared with controls. The study compares 
data for three neurobiological parameters not previously 
studied by the CORE measure: examining neurotrophins 
(BDNF), oxidative stress (protein carbonyl content [PCC] 
and thiobarbituric acid reactive substances [TBARS]), and 




Depressive patients were recruited at the Mood Disorders 
Program, an outpatient facility based at the Hospital de 
Clínicas de Porto Alegre (HCPA), Brazil. A diagnosis of 
unipolar depression was accorded by DSM-IV criteria and 
rated by the Mini International Neuropsychiatric Interview, 
Brazilian version (MINI-Plus).50 All depressed patients were 
classified as melancholic or nonmelancholic according to 
the CORE measure that evaluates 18 observable features 
of melancholia on a four-point scale, measuring its absence 
(“0”) or presence (three levels of severity, from 1 to 3).38 
Examples of items include facial nonreactivity, facial appre-
hension, and delay in motor activity. Three authors (LS, 
MAC, EAV) were trained by video and printed guidelines 
provided by the Black Dog Institute.51 A CORE score 8 
was adopted in this study as defining melancholia, according 
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to CORE development studies.52 Depressive symptoms were 
evaluated using the 17-item Hamilton Depression Rating 
Scale (HDRS-17).53 A HDRS-17 18 indicating moderate 
to severe depression was considered as an inclusion criterion 
for this study.54 Exclusion criteria included any history of 
autoimmune disease, chronic infection, or an inflammatory 
disorder, as well as any severe systemic disease or use of 
immunosuppressive therapy. We also recruited a control 
group consisted of 54 healthy volunteers attending the 
HCPA blood donor center, who had no current or previous 
history as well as no first-degree family history of a major 
psychiatric disorder, including dementia or mental retarda-
tion, assessed by the nonpatient version of the Structured 
Clinical Interview for DSM-IV.
The investigation was approved by the medical ethics 
committee at HCPA, and all participants provided written 
informed consent. All laboratory tests were performed at the 
Laboratory of Molecular Psychiatry, HCPA.
collection and processing of blood
Ten milliliters of blood were collected from each patient and 
control by venipuncture into a free-anticoagulant vacuum 
tube. Immediately after withdrawal, the blood was centri-
fuged at 4,000 rpm for 10 minutes and serum was aliquoted, 
labeled, and stored at -80°C until assayed.
cytokine assay
Serum cytokine concentrations were determined by flow 
cytometry using the BD™ cytometric bead array Th1/Th2/
Th17 Human Cytokine kit (BD Biosciences, San Diego, 
CA, USA). The cytometric bead array kit employed allows 
discrimination of the following cytokines: IL-2, IL-4, IL-6, 
IL-10, TNF-α, IFN-γ, and IL-17A. Sample processing and 
data analyses were performed following the manufacturer’s 
guidelines using a FACSCalibur flow cytometer (BD 
Biosciences). Results were generated in graphical and tabular 
format using FCAP Array™ cytometric bead array analysis 
software (BD Biosciences).
BDNF measurement
Serum concentrations of BDNF were measured by sand-
wich enzyme-linked immunosorbent assay using mono-
clonal antibodies specific for BDNF from R&D Systems 
(Minneapolis, MN, USA). Human BDNF monoclonal 
antibody (clone 37129), a mouse immunoglobulin G2a, 
was used as the capture antibody, and the human BDNF 
biotinylated monoclonal antibody (clone 37141), a mouse 
immunoglobulin G2a, was used as the detection antibody. 
The amount of BDNF was determined by absorbance at 
450 nm with a correction at 540 nm, and the standard curve 
demonstrated a direct relationship between optical density 
and BDNF concentration.
Thiobarbituric acid reactive substances assay
The levels of lipid peroxidation were measured using the 
TBARS assay kit (Cayman Chemical Company, Ann Arbor, 
MI, USA), according to the manufacturer’s instructions. The 
results are expressed in µM of malondialdehyde.
Protein carbonyl content
Oxidative damage to proteins was analyzed by determination 
of carbonyl groups (PCC method for carbonyl content in 
proteins), as previously described by Levine et al.55 Analyses 
were performed in serum samples and the values expressed 
in nmol/mg of protein.
statistical analyses 
All analyses were performed using Statistical Package for the 
Social Sciences version 18 software (SPSS Inc, Chicago, IL, 
USA). The normality of data distribution was examined by 
the Shapiro–Wilk test.56 The chi-square or Fisher’s exact test 
was used to analyze the association between dichotomous cat-
egorical variables. The Student’s t-test was used to compare 
means between unpaired groups. The Mann–Whitney U-test 
was used to compare nonparametric variables between two 
groups. One-way analysis of variance followed by the Tukey 
post hoc test was used for comparison of parametric variables 
among three or more groups, and the Kruskal–Wallis test was 
used for nonparametric variables. Quantitative variables 
were expressed as the mean ± standard deviation or median 
and interquartile range, according to the sample distribution. 
In all experiments, P-values less than 0.05 were considered 
to indicate statistical significance. 
Results
Data from a total of 33 depressed patients were analyzed after 
application of inclusion and exclusion criteria. According to 
the CORE measure, 13 (39.3%) patients were melancholic. 
Demographic and clinical variable data are presented in 
Table 1. There were no significant differences between patient 
groups with regard to age, female sex, HRSD-17, lifetime 
tobacco use, body mass index, time of current episode, 
number of previous episodes, and medication use. While 
CORE-defined melancholic patients had more psychotic 
episodes than nonmelancholic patients (30.8% versus 10%, 
respectively), this difference was not significant.





Our first strategy was to compare the biological 
parameters between depressed patients (irrespective of 
depressive subset) and healthy controls. Table 2 data 
quantify that depressed patients had significantly higher 
levels than controls on the PCC, IL-4, and IL-6 variables. 
There were no differences in other examined biological 
measures.
Laboratory variables for the three groups are presented 
in Table 3. Nonmelancholic patients and controls returned 
higher INF-γ values than melancholic patients, while the 
controls and nonmelancholic patients did not differ from 
each other. Melancholic but not nonmelancholic patients 
returned higher IL-6 values than controls. Melancholic 
patients generated lower TBARS values than nonmelan-
cholic patients, but there was no difference between the 
depressive subset and control groups. Both depressive 
groups showed significantly higher PCC values than controls 
but did not differ between melancholic and nonmelancholic 
groups. There was no statistically significant difference in 
BDNF, IL-2, IL-4, IL-10, TNF-α, and IL-17 levels between 
melancholic and nonmelancholic groups. 
Discussion
We analyzed biological markers in relation to melancholic 
and nonmelancholic depression subtyped by a sign-based 
measure of melancholia. To our knowledge, this is the first 
study evaluating inflammatory markers, neurotrophins, and 
oxidative stress in melancholic depression using a sign-based 
diagnostic tool, ie, the CORE measure. This is also the first 
study comparing oxidative stress parameters (TBARS and 
PCC) irrespective of diagnostic system between melancholic 
and nonmelancholic groups.








age (years) 47.4±9.97 48.4±7.7 52.8±10.7 0.20c
Female sex 74.1% 90.0% 76.9% 0.33a
hDrs Na 21.8±2.9 22.6±2.9 0.81b
lifetime tobacco use Na 55% 53.8% 1.0a
BMi Na 26.4±0.9 27.4±4.4 0.51b
Psychotic depression – 10% 30.8% 0.18a
cOre (mean) Na 3.4±2.5 13.1±5.0 0.001d
Time current episode (average months) – 20.0±18.1 29.0±36.3 0.65d
episodes (n) 0 6.7±7.9 4.3±4.7 0.43d
Proportion on
any aD 0 90% 84.6% 1.0a
Tca 0 50.0% 53.8% 1.0a
ssris 0 65.0% 53.8% 0.41a
Other aD 0 12.1% 0% 0.13a
lithium 0 15.0% 23.1% 0.65a
anticonvulsants 0 45.0% 46.2% 1.0a
antipsychotics 0 25.0% 38.5% 0.46a
Notes: analysis of age and sex comparing three groups, ie, control, nonmelancholic, and melancholic groups; all other variables were analyzed comparing two groups, 
nonmelancholic versus melancholic. Values displayed as the mean ± standard deviation or percentage; achi-square, Fisher’s exact test; bstudent’s t-test; canalysis of variance; 
dMann–Whitney U-test.
Abbreviations: Na, not assessed; hDrs, hamilton Depressive rating scale; BMi, body mass index; aD, antidepressant; Tca, tricyclic antidepressant; ssris, selective 
serotonin reuptake inhibitors.







BDNF 25.11±7.76 26.10±7.40 0.560
TBars 10.26 (4.00) 10.26 (4.66) 0.871
Pcc 0.03 (0.03) 0.69 (0.05) 0.001**
il-2 0.25 (0.08) 0.27 (0.11) 0.578
il-4 0.64 (0.21) 0.75 (0.30) 0.026*
il-6 0.88 (0.69) 1.28 (1.27) 0.004**
il-10 0.37 (0.26) 0.32 (0.28) 0.564
TNF-α 0.98 (0.30) 0.99 (0.26) 0.997
iFN-γ 1.64 (0.34) 1.60 (0.29) 0.316
il-17 12.84 (17.18) 7.87 (9.50) 0.089
Notes: BDNF is displayed as the mean ± standard deviation; other variables are 
displayed as the median and interquartile range. The statistical tests used were one-
way analysis of variance test for BDNF and the Kruskal–Wallis test for other variables. 
*P0.05; **P0.005.
Abbreviations: BDNF, brain-derived neurotrophic factor; TBars, thiobarbituric 
acid reactive substances; Pcc, protein carbonyl content; il-2, interleukin-2; il-4, 
interleukin-4; il-6, interleukin-6; il-10, interleukin-10; il-17, interleukin-17; TNF-α, 
tumor necrosis factor-alpha; iFN-γ, interferon-gamma. 




Biological differences in depressive subtypes
First, we compared all depressed patients (irrespective 
of any subdivision) with controls in relation to potential 
neurobiological markers. We found that PCC, IL-4, and 
IL-6 values were higher in the depressive group, replicating 
previous studies.43,57–59 Other measures (BDNF, IL-2, IL-10, 
IFN-γ, TNF-α, and IL-1 levels) failed to indicate any differ-
ences across groups.
The increase in IL-6 is one of the most consistently 
replicated findings in depressive patients, confirmed in a 
meta-analysis by Dowlati et al43 which also found increased 
TNF-α in depressed patients, albeit not replicated in the cur-
rent study. The higher levels of IL-4 (a Th2 anti-inflammatory 
marker) in depressed patients compared with controls is a less 
consistent finding, with only a few studies reporting this58,59 
and a meta-analysis finding no differences.43 In relation to oxi-
dative stress, the increase in carbonyl products (PCC) in our 
depressive patients is consistent with a study by Magalhaes 
et al in unipolar depressed subjects from a population-based 
sample.57 Whereas PCC has been found to be increased in 
those with a bipolar disorder,57,60 more studies are needed to 
examine this in patients with unipolar depression. Our find-
ings did not replicate the higher TBARS49 and lower BDNF61 
values in depression reported by previous studies, and may 
reflect some limitations to our study (discussed below).
In addition to the differences in neurobiological param-
eters between patients with depression and controls described 
above, we also found biological differences between subsets 
of depressive patients (melancholic and nonmelancholic) 
using the CORE subtyping measure. While differences in 
PCC between depressive patients and controls were evident 
in both depressive subgroups (with no differences between 
those subsets), differences in the inflammatory marker IL-6 
were limited to the melancholic subset in comparison with the 
control group. Moreover, the statistical difference between 
depressive patients and controls in IL-4 disappears, whereas 
differences emerge between depressive subsets in IFN-γ 
and TBARS, with melancholic participants achieving lower 
IFN-γ (than both nonmelancholic patients and controls) and 
TBARS (than nonmelancholic) values.
While there were no differences in the Th1 proinflamma-
tory marker IFN-γ between depressive patients and controls 
in the initial analysis, we found lower values in melancholic 
patients when the depressive groups were split according to 
clinical signs of PMD. This finding is consistent with a study 
by Rothermundt et al10 who found lower IFN-γ and IL-2 lev-
els in melancholic patients, using a symptom-based definition 
of melancholia. They suggested a decrease in cell-mediated 
immunity in patients with melancholic depression, possibly 
induced by hypercortisolemia. Thereby, while melancholic 
depression is classically associated with hypercortisolemia62 
and an increase in plasma adrenocorticotropic hormone,18 
this increase added to an increase in catecholamines (the 
major stress hormones) may systematically inhibit the Th1 
proinflammatory response (via IFN-γ), while upregulating 
Th2 anti-inflammatory production (via IL-4).63 A possible 
explanation for our results is that melancholic depres-
sion may be represented by a specific dysregulation of the 
proinflammatory/anti-inflammatory and Th1/Th2 cytokine 
balance, with a sustained increase in hypercortisolemia and 
catecholamines that then upregulate IL-6 levels.









BDNF 25.11±7.76 25.8±7.5 26.5±7.4 0.80 –
TBars 10.26 (4.00) 10.93 (5.66) 8.93 (2.66) 0.03* NM  M
Pcc 0.03 (0.03) 0.06 (0.03) 0.06 (0.08) 0.001* c  (NM = M) 
il-2 0.25 (0.08) 0.27 (0.12) 0.24 (0.07) 0.65 –
il-4 0.64 (0.21) 0.75 (0.20) 0.81 (0.37) 0.06 –
il-6 0.88 (0.69) 1.28 (1.10) 1.45 (2.55) 0.01* c  M
il-10 0.37 (0.26) 0.28 (0.52) 0.34 (0.25) 0.84 –
TNF-α 0.98 (0.30) 0.97 (0.29) 1.02 (0.35) 0.69 –
iFN-γ 1.64 (0.34) 1.64 (0.72) 1.45 (0.39) 0.01* (c = NM)  M
il-17 12.84 (17.18) 7.51 (9.7) 7.99 (10.02) 0.22 –
Notes: all analysis comparing three groups: control, nonmelancholic, and melancholic groups according to the two models. BDNF is displayed as the mean ± standard 
deviation; other variables are displayed as the median and interquartile range. The last column shows a post hoc comparison between groups according to one-way analysis 
for BDNF or Kruskal–Wallis test for other variables. *indicates statistically significant P-values.
Abbreviations: BDNF, brain-derived neurotrophic factor; TBars, thiobarbituric acid reactive substances; Pcc, protein carbonyl content; il-2, interleukin-2; il-4, 
interleukin-4; il-6, interleukin-6; il-10, interleukin-10; il-17, interleukin-17; TNF-α, tumor necrosis factor-alpha; iFN-γ, interferon-gamma; NM, nonmelancholic group; 
M, melancholic group; c, control group. 





Although the initial higher IL-4 value was not statistically 
significant when we split the depressive group into subsets, 
this change may reflect our small sample size and limited 
statistical power. Similarly, the significance of the higher IL-6 
value was limited to melancholic patients when compared 
with controls, with no differences between depressive 
subtypes when directly compared. Although increased IL-6 
is a well established change in depression43 and is more 
distinctive in melancholic than nonmelancholic patients,27 
our small sample subsets may have compromised our ability 
to demonstrate any such difference.
Turning to oxidative stress markers, the difference in 
PCC was sustained in both depressive subsets when com-
pared with controls, with no difference between subsets. The 
lack of ability of PCC to discriminate depressive subgroups 
may be more a reflection of “depression” than of depressive 
“subtype”. In addition, PCC is not only a sign of oxidative 
stress, but also of protein dysfunction. Carbonyl products 
are altered in a number of systemic diseases, including 
Alzheimer’s disease, inflammation, and diabetes,64 are 
increased consistently in bipolar disorder,57 and may simply 
be a nonspecific marker of disease. Therefore, PCC may 
be seen as a sign of activity in mood disorders, rather than 
a marker of a specific subcategory. On the other hand, we 
found an initially counterintuitive decrease in TBARS, a 
measure of lipid oxidative stress, in melancholic patients 
in comparison with the nonmelancholic group. Most stud-
ies have found no changes57 or reported an increase48,65,66 
in TBARS in depression. To our knowledge, no previous 
studies have investigated TBARS in melancholic depres-
sion, and this result clearly warrants replication as it may 
represent an indirect peripheral metabolic difference in 
depressive subsets. TBARS is a marker of lipid oxidation, 
and is altered according to metabolic status.67 However, 
our sample subtyped by PMD did not differ regarding body 
mass index. Previous studies have used symptoms to subtype 
depressive patients (where nonmelancholic subsets may 
include atypical depression) and differentiate them accord-
ing to patterns of changes in weight and appetite (increased 
in atypical depression and decreased in melancholia). For 
instance,  Lamers et al26 found minimal or no difference 
between melancholic patients and healthy controls across 
several metabolic parameters, although their melancholic 
patients had lower values for some variables (waist circum-
ference and body mass index). On the other hand, atypical 
(nonmelancholic) depression was associated with much 
greater metabolic dysregulation compared with both mel-
ancholic patients and controls. In that study, Lamers et al 
used a modified method to rate depressive subsets, with 
symptoms of weight and appetite distinctly differentiating 
the subgroups of  depression. Although we did not evaluate 
atypical depression or other metabolic markers in our study, 
and body mass index values were no different between sub-
sets, other metabolic differences between depressive subsets 
might be a putative explanation for this finding. 
Most studies examining biological differences (includ-
ing inflammatory markers) in melancholic patients have 
made comparisons with symptom-defined groups with 
nonmelancholic depression, atypical depression, or 
nondepressive controls.9–11,18,27,29–32,34,35,68 Such studies 
have generally reported hypercortisolemia and other 
hypothalamic-pituitary-adrenal axis changes in melancholic 
patients11,18,32,34,69 but contradictory or less robust results 
in relation to inflammatory markers. These contradictory 
results may reflect limitations of symptom-based criteria in 
accurately discriminating the melancholic depressive sub-
type.70 Our results bring a contribution, demonstrating that 
a sign-based criteria set might help to refine the diagnosis 
of melancholia, advancing the search for biological deter-
minants of depressive disorder, with potential therapeutic 
implications.
Our study had a number of limitations. First, the sample 
was small, so had limited statistical power. Second, all 
patients were taking psychiatric medications. Although no 
differences were found in medication classes among the 
groups, antidepressants and neuroleptic medications may 
change inflammatory biomarkers,10,71 levels of BDNF,46 
and oxidative stress parameters.49,66,72 Third, other potential 
variables associated with changes in biomarkers were not 
evaluated, including nutritional status73 and menstrual cycle.74 
Fourth, although observational rating of PMD is necessary 
when using the CORE measure, observable PMD has been 
shown to be less distinctive in younger patients with seem-
ingly true melancholic depression, while a valid rating of 
PMD requires observing patients at or near the nadir of 
their depressive episode.6 While auxiliary tools are being 
developed to complement the assessment, such as the Sydney 
Melancholia Prototype Index,6 only the CORE measure was 
used in the current study.
Diagnoses such as major depression comprise subsets 
of depressive conditions, and there is evidence that each 
may have differing causes, illness trajectories, and treat-
ment responses. Valid identification of one historically 
weighted subset condition (ie, melancholia) may be clini-
cally helpful, and our results add to the body of evidence 
suggesting that this differentiation may contribute to 
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understanding the underlying neurobiology. Although 
psychiatry disorders are generally defined by symptoms, 
clinically observable signs can lead to a more accurate 
diagnosis of melancholia and should be considered in 
future research studies.
Conclusion
Depressive patients differed from healthy controls on three 
biological parameters, returning higher PCC, IL-4, and 
IL-6 values. Melancholic patients classified by a sign-based 
measure (CORE) scored lower across lipid oxidative stress 
markers (versus nonmelancholic patients) and immunological 
markers (versus both controls and nonmelancholic patients). 
A sign-based measure (CORE) used to subtype depressive 
patients demonstrated biological differences across depres-
sive subsets and might enhance accuracy of the clinical diag-
nosis of melancholia. The limitations of our study were that: 
its small sample size may have limited its analytic power; all 
patients were on medication, a potential confounding vari-
able in relation to measuring biological data; and the fact that 
younger patients may show less PMD, limiting the power of 
the CORE measure in this population. 
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